- Home
- NML vs NBP Comparison
NML vs NBP Comparison
Compare NML & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NML | NBP |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 497.5M | 503.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NML | NBP |
|---|---|---|
| Price | $9.25 | $3.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 219.3K | ★ 974.1K |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | ★ 9.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.09 | $0.60 |
| 52 Week High | $7.33 | $6.79 |
Technical Indicators
Market Signals| Indicator | NML | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 69.54 | 39.05 |
| Support Level | $9.09 | $3.05 |
| Resistance Level | $9.34 | $4.08 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 94.69 | 35.58 |
Price Performance
Historical ComparisonAbout NML Neuberger Berman Energy Infrastructure and Income Fund Inc.
Neuberger Berman Energy Infrastructure & Income Fund Inc is a closed-end investment management company based in the United States. Invest in Capital Markets, Chemicals, Oil, Gas & Consumable Fuels, Electric Utilities, Independent Power and Renewable Electricity Producers, Multi Utilities. Maximum is done in Oil, Gas & Consumable Fuels.
About NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.